Teknova Reports Second Quarter 2024 Financial Results

Total revenue in the second quarter of 2024 was $9.6 million, an increase of 3% from the previous quarter.
Raised $15.4 million in equity funding in July 2024
Two new offers launched: Express-Tek^SM Production and RUO+ production quality
Company confirms $35-38 million revenue guidance for 2024

HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading manufacturer of critical reagents for the discovery, development and commercialization of novel therapeutics, vaccines and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2024.